Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 4,900 shares of common stock on January 20, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, the CEO, President, and Chairman of IRADIMED CORP, reported the sale of 4,900 shares of common stock.
• The transactions occurred on January 20, 2026, and were executed under a Rule 10b5-1 trading plan adopted on June 16, 2025.
• The shares were sold in multiple trades at weighted average prices of $101.03, $102.03, and $102.70, with individual trade prices ranging from $100.50 to $102.86.
• The sales were made from the Phillip Susi 2008 Dynasty Trust, for which Roger E. Susi is the reporting person.
• Following these transactions, the Phillip Susi 2008 Dynasty Trust beneficially owns 2,267,500 shares of common stock.
• Roger E. Susi also indirectly beneficially owns 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust, disclaiming beneficial ownership of the latter except for his pecuniary interest.

Sentiment

Score: 5

Explanation: The filing reports planned insider sales by the CEO, which is a neutral event when executed under a 10b5-1 plan, but can sometimes be perceived with slight caution by the market.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity or diversification event rather than a reaction to new, adverse company information.

Negatives

• Insider sales, even when planned, can sometimes be perceived by the market with caution or as a signal that the insider believes the stock price is currently high.

Future Outlook

NA

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
• The transactions were executed in multiple trades at various prices, with the reported price reflecting the weighted average sale price.
• The reporting person disclaims beneficial ownership of certain securities (Matthew Susi 2008 Dynasty Trust) except to the extent of his pecuniary interest therein.

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the insider sales as a signal regarding the company's valuation or future prospects, potentially influencing their investment decisions.

Key Dates

Recommendation

The CEO's sale of shares was executed under a pre-arranged 10b5-1 trading plan, indicating a planned diversification or liquidity event rather than a reaction to new, negative information. While insider sales can sometimes be viewed cautiously, the planned nature mitigates immediate concerns, suggesting a 'hold' stance to observe future company performance and market trends.

Keywords

IRADIMED, IRMD, insider trading, Form 4, stock sale, CEO, 10b5-1 plan, beneficial ownership